VYD2311, a monoclonal antibody for COVID-19, is showing promising Phase 1/2 clinical trial results. With a potential half-life exceeding 139 days, it could serve as a long-lasting alternative to vaccination, especially for immunocompromised individuals. However, concerns about its temporary effects and high cost have sparked debates on its feasibility compared to treatments like Paxlovid. Could this antibody change the game for COVID-19 management? For advertising opportunities, visit Avonetics.com.